Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data

被引:34
作者
Ramamoorthy, Divya [1 ]
Severson, Kristen [2 ,3 ]
Ghosh, Soumya [2 ,3 ]
Sachs, Karen [1 ,4 ]
Glass, Jonathan D. [5 ]
Fournier, Christina N. [5 ]
Herrington, Todd M. [6 ,7 ]
Berry, James D. [6 ]
Ng, Kenney [2 ,3 ]
Fraenkel, Ernest [1 ]
机构
[1] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[2] IBM Res, Ctr Computat Hlth, Cambridge, MA USA
[3] IBM Res, MIT IBM Watson AI Lab, Cambridge, MA USA
[4] Next Generat Analyt, Palo Alto, CA USA
[5] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA
[6] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[7] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA
来源
NATURE COMPUTATIONAL SCIENCE | 2022年 / 2卷 / 09期
关键词
DISEASE ASSESSMENT SCALE; ALSFRS-R; CLINICAL-TRIALS; VITAL CAPACITY; DOUBLE-BLIND; SURVIVAL; C9ORF72; DIAGNOSIS; EFFICACY; DECLINE;
D O I
10.1038/s43588-022-00299-w
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
The clinical presentation of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, varies widely across patients, making it challenging to determine if potential therapeutics slow progression. We sought to determine whether there were common patterns of disease progression that could aid in the design and analysis of clinical trials. We developed an approach based on a mixture of Gaussian processes to identify clusters of patients sharing similar disease progression patterns, modeling their average trajectories and the variability in each cluster. We show that ALS progression is frequently nonlinear, with periods of stable disease preceded or followed by rapid decline. We also show that our approach can be extended to Alzheimer's and Parkinson's diseases. Our results advance the characterization of disease progression of ALS and provide a flexible modeling approach that can be applied to other progressive diseases.
引用
收藏
页码:605 / +
页数:23
相关论文
共 60 条
[1]   Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial [J].
Abe, Koji ;
Aoki, Masashi ;
Tsuji, Shoji ;
Itoyama, Yasuto ;
Sobue, Gen ;
Togo, Masanori ;
Hamada, Chikuma ;
Tanaka, Masahiko ;
Akimoto, Makoto ;
Nakamura, Kazue ;
Takahashi, Fumihiro ;
Kondo, Kazuoki ;
Yoshino, Hiide .
LANCET NEUROLOGY, 2017, 16 (07) :505-512
[2]   Classifying Patients with Amyotrophic Lateral Sclerosis by Changes in FVC A Group-based Trajectory Analysis [J].
Ackrivo, Jason ;
Hansen-Flaschen, John ;
Jones, Bobby L. ;
Wileyto, E. Paul ;
Schwab, Richard J. ;
Elman, Lauren ;
Kawut, Steven M. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 200 (12) :1513-1521
[3]   FIXED DYNAMOMETRY IS MORE SENSITIVE THAN VITAL CAPACITY OR ALS RATING SCALE [J].
Andres, Patricia L. ;
Allred, Margaret ;
Stephens, Helen E. ;
Bunnell, Mary Proffitt ;
Siener, Catherine ;
Macklin, Eric A. ;
Haines, Travis ;
English, Robert A. ;
Fetterman, Katherine A. ;
Kasarskis, Edward J. ;
Florence, Julaine ;
Simmons, Zachary ;
Cudkowicz, Merit E. .
MUSCLE & NERVE, 2017, 56 (04) :710-715
[4]  
[Anonymous], 2019, NAT COMMUN, V10, P4065, DOI [DOI 10.1038/S41467-019-09785-8, 10.1038/s41467-019-11942-y, DOI 10.1038/s41467-019-09785-8, 10.1038/s41467-019-09785-8]
[5]  
[Anonymous], 2020, POOL RES OP ACC ALS
[6]  
[Anonymous], **DATA OBJECT**, DOI DOI 10.5281/ZENODO.6744399
[7]  
Armon C, 2000, MUSCLE NERVE, V23, P874, DOI 10.1002/(SICI)1097-4598(200006)23:6<874::AID-MUS5>3.0.CO
[8]  
2-U
[9]   Diagnosis and Treatment of Parkinson Disease A Review [J].
Armstrong, Melissa J. ;
Okun, Michael S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (06) :548-560
[10]   The PRO-ACT database Design, initial analyses, and predictive features [J].
Atassi, Nazem ;
Berry, James ;
Shui, Amy ;
Zach, Neta ;
Sherman, Alexander ;
Sinani, Ervin ;
Walker, Jason ;
Katsovskiy, Igor ;
Schoenfeld, David ;
Cudkowicz, Merit ;
Leitner, Melanie .
NEUROLOGY, 2014, 83 (19) :1719-1725